|1.||Takeuchi, Masayoshi: 2 articles (05/2004 - 02/2003)|
|2.||Suzuki, T: 1 article (12/2009)|
|3.||Oya-Ito, T: 1 article (12/2009)|
|4.||Uchiyama, K: 1 article (12/2009)|
|5.||Uchida, K: 1 article (12/2009)|
|6.||Takagi, T: 1 article (12/2009)|
|7.||Naito, Y: 1 article (12/2009)|
|8.||Yoshikawa, T: 1 article (12/2009)|
|9.||Hirata, I: 1 article (12/2009)|
|10.||Handa, O: 1 article (12/2009)|
|1.||Diabetic Nephropathies (Diabetic Nephropathy)
03/01/2003 - "CML is a major advanced glycation end product contributing to the development of diabetic nephropathy, and inhibition of its accumulation by OPB-9195 results in amelioration of glomerular lesions in OLETF rats."
03/01/2003 - "The aim of this study is to evaluate histologically the role of N(epsilon)-(carboxymethyl)lysine (CML) in the development of diabetic nephropathy and investigate whether inhibition of CML accumulation by OPB-9195 is associated directly with the prevention of glomerular lesions in OLETF rats. "
05/01/1999 - "We reported earlier that OPB-9195, a synthetic thiazolidine derivative and novel inhibitor of advanced glycation, prevented progression of diabetic glomerulosclerosis by lowering serum concentrations of advanced glycation end products and reducing their deposition in the glomeruli. "
05/01/1999 - "Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195."
05/07/2004 - "This study reports the inhibitory effect of OPB-9195 (OPB), an inhibitor of AGEs formation, and the role of a collagen-specific molecular chaperone, a 47-kDa heat shock protein (HSP47) in diabetic nephropathy. "
|2.||Type 2 Diabetes Mellitus (MODY)
03/01/2003 - "An inhibitor of advanced glycation, OPB-9195, retards the progression of nephropathy in Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a model of non-insulin-dependent diabetes mellitus. "
05/01/1997 - "Otsuka-Long-Evans-Tokushima-Fatty (OLETF) rats, a model of NIDDM, were used to evaluate the therapeutic effect of OPB-9195. "
05/01/1999 - "We also investigated the expression of type IV collagen in the kidneys of Otsuka-Long-Evans-Tokushima-Fatty (OLETF) rats, a Type II (non-insulin-dependent) diabetes mellitus model, after treatment with OPB-9195. "
04/01/2008 - "This diabetes-induced atrial fibrosis was remarkably prevented by administration of an inhibitor of AGEs formation, OPB-9195, along with reduction of CTGF expression. "
02/01/2003 - "We have shown previously that OPB-9195, a novel inhibitor of advanced glycation end products (AGE), significantly prevented renal tubular injury and tubulointerstitial fibrosis in spontaneous diabetic rats. "
|1.||Molecular Chaperones (Chaperone, Molecular)
|2.||Heat-Shock Proteins (Heat-Shock Protein)
|5.||Advanced Glycosylation End Products
|7.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|8.||Intercellular Signaling Peptides and Proteins (Growth Factors)
|9.||Collagen Type IV (Type IV Collagen)
|10.||Transforming Growth Factor beta (TGF-beta)